Physician profile
Matthew Davis
NPI 1629238860
$566,938.75
in general payments reported to CMS, 2019-2025
52 companies · $167K in 2025
The $167K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $564 · 2021: $9,843 · 2022: $108K · 2023: $135K · 2024: $146K · 2025: $167K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $246K · Honoraria: $87K · Consulting Fee: $64K · Travel and Lodging: $32K · Food and Beverage: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,275 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $246,462.00 |
| Honoraria | $87,375.50 |
| Consulting Fee | $64,379.50 |
| Travel and Lodging | $32,398.45 |
| Food and Beverage | $15,463.05 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,275.00 |
| Education | $248.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $257,664.14 | 2019-2025 | |
| Harmony Biosciences LLC | $131,607.23 | 2020-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $108,212.45 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $47,748.76 | 2023-2025 | Sunosi, Symbravo |
| Lilly USA, LLC | $13,659.32 | 2019-2025 | Zepbound, Amyvid, Kisunla |
| Idorsia Pharmaceuticals US INC | $1,791.44 | 2023-2025 | Quviviq, Quviviq |
| Novartis Pharmaceuticals Corporation | $798.11 | 2019-2025 | |
| Pfizer INC. | $676.32 | 2019-2025 | |
| Inspire Medical Systems, INC. | $675.77 | 2025 | Inspire |
| Abbvie INC. | $563.80 | 2021-2025 | Qulipta, Ubrelvy |
| Biogen, INC. | $395.93 | 2019-2025 | Vumerity, Tysabri |
| Ucb, INC. | $322.13 | 2019-2023 | Briviact |
| Lundbeck LLC | $303.88 | 2022-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $260.99 | 2019-2025 | Ajovy, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $230.76 | 2022 |
Show all 50 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.